Company*
(Country; Symbol)
Product Description Indication Status (Date)

AUTOIMMUNE
 
Anacor Pharmaceuticals* AN2728 Topical anti-inflammatory product Psoriasis Phase II achieved its objective in of defining the optimal duration of therapy (2/19)
 
Hutchison Media-Pharma Ltd. (UK) HMPL-004 An oral botanical product that acts on multiple inflammatory products Crohn's disease Completed patient enrollment in a 100-patient Phase II trial (2/17)
 
Theravance Inc. (THRX) and GlaxoSmithKline plc (UK) ­ Inhaled corticosteroid fluticasone furoate Mild, moderate and severe asthma Phase IIb data showed that once-daily FF produced statistically significant improvements in patients' lung function compared to placebo (2/4)
 
CANCER
 
Allos Therapeutics Inc. (ALTH) Pralatrexate Novel antifolate Peripheral T-cell lymphoma Pivotal Phase II data showed an estimated median duration of response of 287 days, or 9.4 months, a secondary endpoint of the trial (2/4)
 
Ascenta Therapeutics Inc.* AT-101 A pan-Bcl-2 inhibitor Prostate cancer Phase II data showed it can be safely administered in combination with docetaxel and prednisone (2/27)
 
AVEO Pharmaceuticals Inc.* AV-951 VEGF inhibitor Advanced renal cell carcinoma Phase II data showed a 91.7% disease control rate and a 20.1% objective response rate in treated patients (2/25)
 
Cougar Biotechnology Inc. (CGRB) CB7630 Abiraterone acetate Prostate cancer Phase II data showed 77% of patients experienced a decline in prostate-specific antigen levels of greater than 30%, 22% experienced a decline of 50% or more and 26% had a decline of more than 90% (2/27)
 
Curis Inc. (CRIS) and Genentech Inc. (NYSE:DNA) GDC-0449 An orally-administered small- molecule Hedgehog Pathway inhibitor Metastatic or locally advanced basal cell carcinoma Treated the first patient in a pivotal Phase II trial (2/12)
 
Endocyte Inc.* EC145 A folate-targeted cyto-toxic drug Platinum-resistant ovarian cancer Started a Phase II trial (2/19)
 
Peregrine Pharmaceuticals Inc. (PPHM) Bavituximab Monoclonal antibody that binds to phosphatidylserine Non-small-cell lung cancer; breast cancer Met its tumor response endpoint when used with chemotherapy in a Phase II trial in NSCLC (2/4); half of study patients achieved tumor response after two treatment cycles in a Phase II breast cancer study (2/11)
 
Poniard Pharmaceuticals Inc. (PARD) Picoplatin Platinum chemotherapy agent Metastatic castration-resistant prostate cancer Phase II data of picoplatin in combination with docetaxel and prednisone showed it is active as a first-line therapy (2/25)
 
Seattle Genetics Inc. (SGEN) SGN-33 Lintuzumab Acute myeloid leukemia Completed patient enrollment in a Phase IIb trial (2/25)
 
CARDIOVASCULAR
 
Aastrom Biosciences Inc. (ASTM) CRCs Cardiac repair cells Heart failure Suspended Phase II enrollment while FDA reviews an incident  under which a patient developed a serious adverse event associated with anesthesia management (2/2)
 
Alkermes Inc. (ALKS) ALKS 27 An inhaled formulation of trospium based on Alkermes' AIR pulmonary technology Chronic obstructive pulmonary disease Began a Phase IIa study (2/18)
 
Arena Pharmaceuticals Inc. (ARNA) ­ Niacin receptor agonist Atherosclerosis Began a Phase II trial (2/18)
 
BioMarin Pharmaceutical Inc. (BMRN) 6R-BH4 Sapropterin dihydro-chloride Symptomatic peripheral arterial disease Phase II data showed no statistical significance between treatment and placebo groups (2/3)
 
Ligand Pharmaceuticals Inc. (LGND) PS433540 First-in-class dual-acting receptor agonist that targets the angiotensin and endothelin receptors Hypertension Phase IIb data showed it was safe and well tolerated and demonstrated statistically significant greater reductions in blood pressure than placebo (2/2)
 
Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) ­ Beta-human chorionic gonadotropin and erythropoietin Acute ischemic stroke Phase IIa data showed no safety concerns, and all 12 patients improved (2/19)
 
ThromboGenics NV (Belgium; BR:THR) and BioInvent International AB (Sweden; SSE:BINV) TB-402 Long-acting antibody that targets part of Factor VIII Deep vein thrombosis Started a 300-patient, Phase II trial (2/23)
 
CENTRAL NERVOUS SYSTEM
 
Corcept Therapeutics Inc. (CORT) Corlux Cortisol receptor antagonist Psychotic depression Secondary endpoint analysis showed that the addition of Corlux to Risperdal resulted in less abdominal fat, lower fasting insulin levels and lower tri-glyceride levels, all of which were statistically significant compared to Risperdal alone (2/23)
 
ExonHit Therapeutics SA (France; Paris:ALEHT) EHT 0202 Stimulates the alpha-secretase pathway Alzheimer's disease Completed patient enrollment in a Phase IIa trial (2/26)
 
Minster Pharmaceuticals plc (UK; LSE:MPM) Tonabersat A neuronal gap junction blocker To prevent migraine Failed in a Phase IIb trial (2/2)
 
Rexahn Pharmaceuticals Inc. (AMEX:RNN) Serdaxin An oral, extended-release tablet Major depressive disorder Started a Phase IIa trial (2/2)
 
DIABETES
 
Arete Therapeutics Inc.* AR9281 An orally administered soluble epoxide hydrolase inhibitor Type II diabetes Started a Phase IIa trial (2/10)
 
ConjuChem Biotechnologies Inc. (Canada; TSX:CJB) PC-DAC: Exendin-4 GLP-1 agonist Diabetes Phase II data confirm that it significantly reduced HbA1c and weight compared to placebo (2/10)
 
CPEX Pharmaceuticals Inc. (CPEX) Nasulin Intranasal insulin candidate Type II diabetes Started a Phase II trial (2/24)
 
Transition Therapeutics Inc. (Canada; TTHI) TT-223 Gastrin analogue Type II diabetes Completed patient enrollment for a Phase II study (2/5)
 
INFECTION
 
BioCryst Pharmaceuticals Inc. (BCRX) Peramivir A neuraminidase inhibitor Influenza Phase II data showed no statistically significant differences among two doses of once-daily peramivir and twice-daily oseltamivir (2/23)
 
GeoVax Labs Inc. (OTC BB: GOVX) ­ Two-component vaccine,  a recombinant DNA and a recombinant modified vaccinia Ankara HIV/AIDS Began a Phase IIa trial (2/20)
 
PharmAthene Inc. (AMEX:PIP) SparVax Second-generation recombinant protective anthrax vaccine candidate Anthrax Phase II data suggested that it may be a promising protective anthrax vaccine for civilian defense (2/24)
 
Raptor Pharmaceuticals Corp. (OTC BB: RPTP) Cysteamine Cysteamine bitartrate Nonalcoholic steatohepatitis Completed patient enrollment in its Phase IIa trial (2/5)
 
Romark Laboratories* Nitazoxanide First of a new class of broad-spectrum antiviral drugs known as thiazolides Hepatitis C virus Phase II data showed that 82% and 100% of treatment-naive patients experienced undetectable serumHCV RNA after 12 weeks when treated with low and high dosages of nitazoxanide in combination with peginterferon and ribavirin (2/17)
 
MISCELLANEOUS
 
Amicus Therapeutics Inc. (FOLD) AT2220 1-deoxynojirimycin HCl Pompe disease Company suspended further enrollment and the FDA issued a clinical hold when two patients experienced serious adverse events that were probably treatment-related (2/27)
 
Capstone Therapeutics* AZX100 A synthetic 24 amino acid peptide Dermal scarring Began dosing in a Phase II trial (2/10)
 
CyDex Pharmaceuticals Inc.* Captisol-Enabled Budesonide/Zelastine nasal spray Seasonal allergic rhinitis Completed a Phase II with 108 patients (2/3)
 
ESBATech AG* (Switzerland) ESBA105 A single-chain antibody fragment directed against TNF-alpha Acute anterior uveitis Started a Phase IIa study (2/24)
 
Genzyme Corp. (GENZ) Genz-112638 Oral therapy Gaucher disease Phase II data showed it met its primary endpoint (2/20)

Notes:

* Privately held.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.